Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России, Омск, Россия dmitry_trukhan@mail.ru
Список исп. литературыСкрыть список 1. Cheng YO, Veettil SK, Syeed MS, Shetty NY, Gopinath D. Comparative efficacy of therapeutic interventions for the management of recurrent aphthous ulcers: a systematic review and network meta-analysis. J Evid Based Dent Pract. 2023;23(4):101918. DOI: 10.1016/j.jebdp.2023. 101918 2. Волков Е.А., Бутова В.Г., Позднякова Т.И., Дзугаева И.И. Клинические рекомендации (протокол лечения) хронический рецидивирующий афтозный стоматит. Российский стоматологический журнал. 2014;5: 35-49. https://www.elibrary.ru/item.asp?id=22512498 Volkov E.A., Butova V.G., Pozdnyakova T.I., Dzugaeva I.I. Klinicheskie rekomendacii (protokol lecheniya) xronicheskij recidiviruyushhij aftozny`j stomatit. Rossijskij stomatologicheskij zhurnal. 2014;5: 35-49. https://www.elibrary.ru/item.asp?id=22512498 (in Russian). 3. Gomes CC, Gomez RS, Zina LG, Amaral FR. Recurrent aphthous stomatitis and Helicobacter pylori. Med Oral Patol Oral Cir Bucal. 2016;21(2):e187-91. DOI: 10.4317/medoral.20872 4. Li L, Gu H, Zhang G. Association between recurrent aphthous stomatitis and Helicobacter pylori infection: a meta-analysis. Clin Oral Investig. 2014;18(6):1553-60. DOI: 10.1007/s00784-014-1230-5 5. Adler I, Muiño A, Aguas S et al. Helicobacter pylori and oral pathology: relationship with the gastric infection. World J Gastroenterol. 2014;20(29):9922-35. DOI: 10.3748/wjg.v20.i29.9922 6. Gülseren D, Karaduman A, Kutsal D, Nohutcu RM. The relationship between recurrent aphthous stomatitis, and periodontal disease and Helicobacter Pylori infection. Clin Oral Investig. 2016;20(8):2055-60. DOI: 10.1007/s00784-015-1704-0 7. Karaca S, Seyhan M, Senol M, Harputluoglu MM, Ozcan A. The effect of gastric Helicobacter pylori eradication on recurrent aphthous stomatitis. Int J Dermatol. 2008;47(6):615-7. DOI: 10.1111/j.1365-4632.2008.03667.x 8. Gao Y, Gupta N, Abdalla M. Recurrent Aphthous Stomatitis Improved after Eradication Therapy for Helicobacter pylori. Case Rep Gastrointest Med. 2021;2021:5543838. DOI: 10.1155/2021/5543838 9. Albanidou-Farmaki E, Giannoulis L, Markopoulos A et al. Outcome following treatment for Helicobacter pylori in patients with recurrent aphthous stomatitis. Oral Dis. 2005;11(1):22-6. DOI: 10.1111/j.1601-0825.2004.01053.x 10. Taş DA, Yakar T, Sakalli H, Serin E. Impact of Helicobacter pylori on the clinical course of recurrent aphthous stomatitis. J Oral Pathol Med. 2013;42(1):89-94. DOI: 10.1111/j.1600-0714.2012.01197.x 11. Shen J, Ye Z, Xie H et al. The relationship between Helicobacter pylori infection and recurrent aphthous stomatitis: a systematic review and meta-analysis. Clin Oral Investig. 2023 Nov;27(11):6345-56. DOI: 10.1007/s00784-023-05273-y 12. Bhargava S, Dubey SP, Haldipur D et al. Management of Recurrent Aphthous Stomatitis: An Indian Expert Consensus. Indian J Otolaryngol Head Neck Surg. 2023;75(3):2672-80. DOI: 10.1007/s12070-023-03708-2 13. Matysiak-Budnik T, Heyman M, Megraud F. Review article: rebamipide and the digestive epithelial barrier. Aliment Pharmacol Ther. 2003;18 (Suppl. 1):55-62. DOI: 10.1046/j.1365-2036.18.s1.6.x 14. Arakawa T, Higuchi K, Fujiwara Y et al. 15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications. Dig Dis Sci. 2005;50 (Suppl. 1):S3-S11. DOI: 10.1007/s10620-005-2800-9 15. Fujiwara Y, Higuchi K, Tominaga K et al. Quality of ulcer healing and rebamipide. 2005;63 (Suppl. 11):397-400. Available at: https://www. ncbi.nlm.nih.gov/pubmed/16363567 16. Naito Y, Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol. 2010;4(3):261-70. DOI: 10.1586/ egh.10.25 17. Zhang S, Qing Q, Bai Y et al. Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis. Dig Dis Sci. 2013;58(7):1991-2000. DOI: 10.1007/s10620-013-2606-0 18. Симаненков В.И., Маев И.В., Ткачева О.Н. и др. Синдром повышенной эпителиальной проницаемости в клинической практике. Мультидисциплинарный национальный консенсус. Кардиоваскулярная терапия и профилактика. 2021;20(1):2758. DOI: 10.15829/1728-8800-2021-2758 Simanenkov V.I., Maev I.V., Tkacheva O.N. et al. Syndrome of increased epithelial permeability in clinical practice. Multidisciplinary national Consensus. Cardiovascular Therapy and Prevention. 2021;20(1):2758. DOI: 10.15829/1728-8800-2021-2758 (in Russian). 19. Suetsugu H, Ishihara S, Moriyama N et al. Effect of rebamipide on prostaglandin EP4 receptor gene expression in rat gastric mucosa. J Lab Clin Med. 2000;136(1):50-7. DOI: 10.1067/mlc.2000.107303 20. Fujioka T, Arakawa T, Shimoyama T et al. Effects of rebamipide, a gastro-protective drug on the Helicobacter pylori status and inflammation in the gastric mucosa of patients with gastric ulcer: a randomized double-blind placebo-controlled multicentre trial. Aliment Pharmacol Ther. 2003;18 (Suppl 1):146-52. DOI: 10.1046/j.1365-2036.18.s1.20.x 21. Kleine A, Kluge S, Peskar BM. Stimulation of prostaglandin biosynthesis mediates gastroprotective effect of rebamipide in rats. Dig Dis Sci. 1993;38(8):1441-9. DOI: 10.1007/bf01308601 22. Sun WH, Tsuji S, Tsujii M et al. Induction of cyclooxygenase-2 in rat gastric mucosa by rebamipide, a mucoprotective agent. J Pharmacol Exp Ther. 2000;295(2):447-52. URL: https://www.ncbi.nlm.nih.gov/ pubmed/11046075 23. Yoshida N, Yoshikawa T, Iinuma S et al. Rebamipide protects against activation of neutrophils by Helicobacter pylori. Dig Dis Sci. 1996;41(6):1139-44. DOI: 10.1007/bf02088229 24. Arakawa T, Kobayashi K, Yoshikawa T. Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci. 1998;43(9):5-13. 25. Du Y, Li Z, Zhan X et al. Anti-inflammatory effects of rebamipide according to Helicobacter pylori status in patients with chronic erosive gastritis: a randomized sucralfate-controlled multicenter trial in China-STARS study. Dig Dis Sci. 2008;53(11):2886-95. DOI: 10.1007/ s10620-007-0180-z 26. Masamune A, Yoshida M, Sakai Y, Shimosegawa T. Rebamipide inhibits ceramide-induced interleukin-8 production in Kato III human gastric cancer cells. J Pharmacol Exp Ther. 2001;298(2):485-92. URL: https://www.ncbi.nlm.nih.gov/pubmed/11454909 27. Sugimoto M, Uotani T, Furuta T. Does rebamipide prevent gastric mucosal injury in patients taking aspirin and clopidogrel? Dig Dis Sci. 2014;59(8):1671-3. DOI: 10.1007/s10620-014-3145-z 28. Suzuki T, Yoshida N, Nakabe N et al. Prophylactic effect of rebamipide on aspirin-induced gastric lesions and disruption of tight junctional protein zonula occludens-1 distribution. J Pharmacol Sci. 2008;106(3):469-77. DOI: 10.1254/jphs. FP0071422 29. Mizukami K, Murakami K, Abe T et al. Aspirin-induced small bowel injuries and the preventive effect of rebamipide. World J Gastroenterol. 2011;17(46):5117-22. DOI: 10.3748/wjg.v17.i46.5117 30. Nishizawa T, Suzuki H, Nakagawa I et al. Rebamipide-promoted restoration of gastric mucosal sonic hedgehog expression after early Helicobacter pylori eradication. Digestion. 2009;79(4):259-62. DOI: 10.1159/000213241. 31. Tarnawski AS, Jones MK. The role of epidermal growth factor (EGF) and its receptor in mucosal protection, adaptation to injury, and ulcer healing: involvement of EGF-R signal transduction pathways. J Clin Gastroenterol. 1998;27 (Suppl 1):S12-20. DOI: 10.1097/00004836-199800001-00004 32. Tarnawski AS, Chai J, Pai R, Chiou SK. Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action? Dig Dis Sci. 2004;49(2):202-9. DOI: 10.1023/b:ddas.0000017439.60943.5c 33. Udagawa A, Shiota G, Ichiba M, Murawaki Y. Effect of rebamipide on acetic acid-induced gastric ulcer in rats: involvement of hepatocyte growth factor. Scand J Gastroenterol. 2003;38(2):141-6. DOI: 10.1080/00365520310000609 34. Watanabe S, Wang XE, Hirose M et al. Effects of rebamipide on bile acid-induced inhibition of gastric epithelial repair in a rabbit cell culture model. Aliment Pharmacol Ther. 1996;10(6):927-32. DOI: 10.1046/j.1365-2036.1996.105276000.x 35. Hahm KB, Park IS, Kim YS et al. Role of rebamipide on induction of heat-shock proteins and protection against reactive oxygen metabolite-mediated cell damage in cultured gastric mucosal cells. Free Radic Biol Med. 1997;22(4):711-6. DOI: 10.1016/s0891-5849(96)00406-6 36. Masanobu T, Tomoya T, Asano R et al. Rebamipide suppresses 5-fluorouracil-induced cell death via the activation of Akt/mTOR pathway and regulates the expression of Bcl-2 family proteins. Toxicology in Vitro. 2018;46:284-93. DOI: 10.1016/j.tiv.2017.10.019 37. Rao JN, Guo X, Liu L et al. Polyamines regulate Rho-kinase and myosin phosphorylation during intestinal epithelial restitution. Am J Physiol Cell Physiol. 2003;284:848-59. DOI: 10.1152/ ajpcell.00371.2002 38. Takagi T, Naito Y, Uchiyama K et al. Rebamipide promotes healing of colonic ulceration through enhanced epithelial restitution. World J Gastroenterol. 2011;17(33):3802-9. DOI: 10.3748/wjg.v17.i33.3802 39. Suzuki H, Mori M, Kai A et al. Effect of rebamipide on H. pylori-associated gastric mucosal injury in Mongolian gerbils. Dig Dis Sci. 1998;43 (9 Suppl):181S-187S. URL: https://www.ncbi.nlm.nih.gov/pubmed/ 9753247 40. Hayashi S, Sugiyama T, Amano K et al. Effect of rebamipide, a novel antiulcer agent, on Helicobacter pylori adhesion to gastric epithelial cells. Antimicrob Agents Chemother. 1998;42(8):1895-9. URL: https:// www.ncbi.nlm.nih.gov/pmc/articles/PMC105706/ 41. Meghanadh KR, Kaur M, Haldipur D et al. Rebamipide in Recurrent Aphthous Stomatitis: review of indian evidence. The Indian Practitioner. 2021;74:30-5. URL: https://www.wosonhj.com/scholar/367091xs.html 42. Jadhav A, Marathe S, Mhapuskar A, Jadhav S. To evaluate the efficacy of rebamipide on clinical resolution and recurrence of minor recurrent aphthous stomatitis. Int J Dent Health Sci. 2015;2:781-797. URL: https://www.researchgate.net/publication/299617275_TO_EVALUATE_THE_EFFICACY_OF_REBAMIPIDE_ON_CLINICAL_RESOLUTION_AND_RECURRENCE_OF_MINOR_RECURRENT_APHTHOUS_STOMATITIS 43. Hasan S, Perween N, Saeed S, Kaur M, Gombra V, Rai A. Evaluation of 5% Amlexenox Oral Paste and Rebamipide Tablets in Treatment of Recurrent Apthous Stomatitis and Comparison with Dologel CT. Indian J Otolaryngol Head Neck Surg. 2022;74(Suppl 3):5228-34. DOI: 10.1007/s12070-020-01858-1 44. Uppalwar P, Kunjir G, Krishna Kumar R et al. Comparison of therapeutic effect of topical Amlexanox (5%), and oral Rebamipide (100 mg) in the management of oral aphthous ulceration. J Oral Dent Health. 2016;2:6–8. URL: https://scholar.google.com/scholar?hl=ru&as_ sdt=0%2C5&q=Comparison+of+therapeutic+effect+of+topical+Amlexanox+%285%25%29%2C+and+oral+Rebamipide+%28100+mg%29+in+the+management+of+oral+aphthous+ulceration&btnG= 45. Hasan S, Mohd. Faisal Siddique. Management of major recurrent aphthous ulcers with 5% amlexanox oral paste and rebamipide tablets- A case report with a brief literature review. IP Int J Periodontol Implantol. 2023;8(4):225-9. DOI: 10.18231/j.ijpi.2023.043 46. Parvathi Devi MK, Ramesh DN, Koppal S et al. Efficacy of rebamipide and levamisole in the treatment of patients with recurrent aphthous ulcer – a comparative study. J Clin Diagn Res. 2014;8(11):ZC119-22. DOI: 10.7860/JCDR/2014/10295.5202 47. Kudur MH, Hulmani M. Rebamipide: A Novel Agent in the Treatment of Recurrent Aphthous Ulcer and Behcet's Syndrome. Indian J Dermatol. 2013;58(5):352-4. DOI: 10.4103/0019-5154.117298 48. Taylor J, Glenny AM, Walsh T et al. Interventions for the management of oral ulcers in Behçet's disease. Cochrane Database Syst Rev. 2014;2014(9):CD011018. DOI: 10.1002/14651858.CD011018.pub2 49. Lau CB, Smith GP. Recurrent aphthous stomatitis: A comprehensive review and recommendations on therapeutic options. Dermatol Ther. 2022;35(6):e15500. DOI: 10.1111/dth.15500 50. Matsuda T, Ohno S, Hirohata S et al. Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behçet's disease: a randomised, double-blind, placebo-controlled study. Drugs R D. 2003;4(1):19-28. DOI: 10.2165/00126839-200304010-00002 51. Kawano Y, Hanawa T. Development of Hospital Formulations Based on Medical Need. Yakugaku Zasshi. 2019;139(10):1275-80. DOI: 10.1248/yakushi.19-00121-2 52. Enami A, Masuda N, Yamamura J, et al. Therapeutic effect of rebamipide for oral mucositis associated with FEC therapy for breast cancer. Gan To Kagaku Ryoho. 2014;41(11):1407-12. URL: https://pubmed. ncbi.nlm.nih.gov/25434444/ 53. Ishii N, Mizobuchi S, Kawano Y, Hanawa T. Preparation and Evaluation of a Powdered Rebamipide Mouthwash as In-Hospital Formulation: Considering Dispersion before Use in Patients. Pharmaceutics. 2021;13(11):1848. DOI: 10.3390/pharmaceutics13111848 54. Nakashima T, Sako N, Matsuda T, Uematsu N et al. Novel submicronized rebamipide liquid with moderate viscosity: significant effects on oral mucositis in animal models. Biol Pharm Bull. 2014;37(4):671-8. DOI: 10.1248/bpb.b13-01006 55. Nakashima T, Uematsu N, Sakurai K. Intra-oral administration of rebamipide liquid prevents tongue injuries induced by X-ray irradiation in rats. Support Care Cancer. 2017;25(7):2205-13. DOI: 10.1007/ s00520-017-3626-7 56. Yasuda T, Chiba H, Satomi T et al. A pilot study of rebamipide-gargle for chemoradiotherapy-induced mucositis in oral cancer patient. Gan To Kagaku Ryoho. 2008;35(7):1157-61. URL: https://pubmed.ncbi. nlm.nih.gov/18633254/ 57. Kabeya M, Ina K, Yuasa S et al. Pilot study on clinical effects of rebamipide gargle against oral mucositis induced by fluoropyrimidines. Gan To Kagaku Ryoho. 2011l;38(7):1133-6. URL: https://pubmed. ncbi. nlm.nih.gov/21772097/ 58. Ishii N, Kawano Y, Sakai H et al. Effects of a Rebamipide Mouthwash on Stomatitis Caused by Cancer Chemotherapy-Evaluation of the Efficacy by Patients Themselves. Yakugaku Zasshi. 2017;137(8):1027-34. DOI: 10.1248/yakushi.17-00042 59. Takeuchi I, Togo C, Makino K. Rebamipide-containing Film Using Chitosan and HPMC for Oral Mucositis Induced by Cancer Chemotherapy. Anticancer Res. 2019;39(12):6531-36. DOI: 10.21873/anticanres. 13868 60. Shinohara A, Nakamura M, Onikubo T, Nakamura K. Efficacy of Rebamipide Gargle against Chemotherapy-induced Oral Mucositis. Yakugaku Zasshi. 2015;135(8):937-41. DOI: 10.1248/yakushi.15-00112-2 61. Chaitanya B, Pai KM, Yathiraj PH et al. Rebamipide gargle in preventive management of chemo-radiotherapy induced oral mucositis. Oral Oncol. 2017;72:179-82. DOI: 10.1016/j.oraloncology.2017. 07.024 62. Yokota T, Ogawa T, Takahashi S et al. Efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II study. BMC Cancer. 2017;17(1):314. DOI: 10.1186/s12885-017-3295-4 63. Akagi S, Fujiwara T, Nishida M et al. The effectiveness of rebamipide mouthwash therapy for radiotherapy and chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a systematic review and meta-analysis. J Pharm Health Care Sci. 2019;5:16. DOI: 10.1186/s40780-019-0146-2 64. Трухан Д.И., Иванова Д.С. Лекарственная безопасность в реальной клинической практике: акцент на протекторную терапию. Фарматека. 2022; 29(3):72-82. DOI: 10.18565/pharmateca.2022.3.72-82 Trukhan D.I., Ivanova D.S. Drug safety in real clinical practice: focus on protective therapy. Farmateka. 2022;29(3):72-82. DOI: 10.18565/ pharmateca.2022.3.72-8 (in Russian).